BYD Rolls Off Its 3 Millionth New Energy Vehicle and Debuts A New Passenger Car Brand Matrix
16.11.2022 15:18:00 EET | Business Wire | Press release
On November 16, the roll-off production line ceremony of BYD's 3 millionth new energy vehicle was held at BYD's global headquarters. It was not only a symbolic milestone for BYD but also an important achievement for the development of new energy vehicles worldwide. While it took BYD 13 years to achieve the first one million new energy vehicle landmark, just one year later, BYD accomplished the milestone from "one million to two million new energy vehicles". Now, just in 6 months, BYD reached the milestone of " from two million to three million new energy vehicles". BYD has showcased a massive "acceleration" in the new energy vehicle industry, facilitating the rapid change of global green mobility. At the ceremony, Mr. Wang Chuanfu, Chairman and President of BYD, expressed his sincere gratitude to BYD customers, media friends, industry partners, peers, and employees.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221116005467/en/
The roll-off Production Ceremony (Photo: Business Wire)
At the event, Wang Chuanfu, Chairman and President of BYD, delivered the 3 millionth new energy vehicle to Wang Shuang, a soccer player who was named Asian Football Confederation (AFC) Women’s Player of the Year in 2018. “It is a great honor to be the owner of BYD's 3 millionth new energy vehicle”, said Wang Shuang, “I hope everyone can support sustainable mobility to help Cool the Earth by 1℃ and show our strength to the world.”
“Dealing with the industrial transformation and the ever-changing consumption trends in the future, BYD will continue to focus on scientific and technological innovation. In addition to that, BYD will keep on fulfilling people’s pursuit for a better life with leading technologies and diversified products”, said Wang Chuanfu.
He also stated that building on the existing “four-in-one” security system that guarantees the safety of battery’s raw materials, battery cells, battery packs, and vehicles, BYD would introduce another pioneering technology to further improve the security system. “To reassure our customers about safety, we have made it a mission that we will carry to the end”, said Wang Chuanfu.
During the event, Wang Chuanfu announced that BYD would build a high-end brand targeting the luxury market, Yangwang, with disruptive technologies and products. Its upcoming model will launch in the first quarter of 2023, bringing users unprecedented high performance.
In addition, in 2023, BYD will release a new brand grounded in highly professional and personalized identities, to meet the diversified demand of consumers. The brand will harness the co-creation with users and warmly welcome all the franchised dealerships to join BYD for its promotion.
In the future, BYD Auto will form a powerful brand matrix including BYD (Dynasty & Ocean), Denza, Yangwang, and another new brand that specializes in professional and personalized identities, covering family cars and luxury cars. With popularized and personalized design, BYD will constantly provide high-quality products that address customers' ever-rising expectations.
Furthermore, BYD will adhere to its global strategy by further developing the global market and promoting the passenger vehicle industry globally. Currently, BYD has extended its new energy vehicle footprint to over 400 cities across 70 countries and regions on 6 continents.
The roll-off of the 3 millionth NEV is not only an important milestone in BYD's history but also the vital landmark of witnessing the acceleration of global green mobility. In the future, BYD will continue to cooperate with partners from various sectors to achieve high-quality development. Under this collaboration, BYD will also persist in facilitating the progress of the global new energy vehicle industry and accelerating the transition of our mother planet to become a greener world.
About BYD
BYD is a multinational high-tech company devoted to leveraging technological innovations for a better life. Founded in 1995 as a rechargeable battery maker, BYD now boasts a diverse business scope covering automobiles, rail transit, new energy, and electronics, with over 30 industrial parks in China, the United States, Canada, Japan, Brazil, Hungary, and India. From energy generation and storage to its applications, BYD is dedicated to providing zero-emission energy solutions that reduce global reliance on fossil fuels. Its new energy vehicle footprint now covers 6 continents, over 70 countries and regions, and more than 400 cities. Listed in both Hong Kong and Shenzhen Stock Exchanges, the company is known to be a Fortune Global 500 enterprise that furnishes innovations in pursuit of a greener world.
For more information, please visit www.bydglobal.com.
About BYD Auto
Founded in 2003, BYD Auto is the automotive subsidiary of BYD, a multinational high-tech company devoted to leveraging technological innovations for a better life. Aiming to accelerate the green transition of the global transportation sector, BYD Auto focuses on developing pure electric and plug-in hybrid vehicles. The company has mastered the core technologies of the entire industrial chain of new energy vehicles, such as batteries, electric motors, electronic controllers, and automotive-grade semiconductors. It has witnessed in recent years significant technological advancements, including the Blade Battery, the DM-i and DM-p hybrid technology, the e-Platform 3.0, and the CTB technology. The company is the world’s first carmaker to stop the production of fossil-fueled vehicles on EV shift and has remained top of new energy passenger vehicle sales in China for 9 years in a row.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005467/en/
Contact information
Asia-Pacific: Mia Gu, mia.gu@byd.com tel: +86-755-8988-8888-69666
Europe: Penny Peng, PressEU@byd.com tel: +31-102070888
North America: Frank Girardot, frank.girardot@byd.com tel: +1 213 245 6503
Latin America: Sofίa Mardones, sofia.mardones@byd.com tel: +56 9 9821 6851
Brazil: Adalberto Maluf, adalberto.maluf@byd.com tel: +19 3514 2554
Africa: Nikki Li, li.namin@byd.com tel: +86-18938862670
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
